GALMED PHARMACEUTICALS LTD.

Analyst Reco. Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Real-time Estimate Cboe BZX Other stock markets 10:22:34 2024-07-09 am EDT			5-day change	1st Jan Change
0.296 ^USD	+1.79%		+9.04%	-31.63%

May. 30	Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 04	Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Maxim Upgrades Galmed Pharmaceuticals to Buy From Hold, Price Target is $4	23-07-24	MT
Maxim Group Downgrades Galmed Pharmaceuticals to Hold From Buy	22-08-08	MT
Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1 From $5	22-08-08	MT
Cantor Fitzgerald Downgrades Galmed Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $0.70 From $5	22-08-04	MT
Raymond James Downgrades Galmed Pharmaceuticals to Market Perform From Outperform	22-05-18	MT
HC Wainwright Downgrades Galmed Pharmaceuticals to Neutral From Buy	22-05-03	MT
Raymond James Adjusts Price Target on Galmed Pharmaceuticals to $5 From $14, Keeps Outperform Rating	22-05-03	MT
GALMED PHARMACEUTICALS : HC Wainwright & Co. Adjusts Price Target on Galmed Pharmaceuticals to $25 From $29, Maintains Buy Rating	21-03-19	MT
GALMED PHARMACEUTICALS : Canaccord Genuity Adjusts Price Target on Galmed Pharmaceuticals to $20 From $25, Maintains Buy Rating	20-11-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer